 Connection
Michael Bristow to Time Factors
This is a "connection" page, showing publications Michael Bristow has written about Time Factors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.257 |
|
|
|
-
Saxon LA, Olshansky B, Volosin K, Steinberg JS, Lee BK, Tomassoni G, Guarnieri T, Rao A, Yong P, Galle E, Leigh J, Ecklund F, Bristow MR. Influence of left ventricular lead location on outcomes in the COMPANION study. J Cardiovasc Electrophysiol. 2009 Jul; 20(7):764-8.
Score: 0.037
-
Dimond MG, Ibrahim NE, Fiuzat M, McMurray JJV, Lindenfeld J, Ahmad T, Bozkurt B, Bristow MR, Butler J, Carson PE, Felker GM, Jessup M, Murillo J, Kondo T, Solomon SD, Abraham WT, O'Connor CM, Psotka MA. Left Ventricular Ejection Fraction and the Future of Heart?Failure Phenotyping. JACC Heart Fail. 2024 Mar; 12(3):451-460.
Score: 0.026
-
Piccini JP, Dufton C, Carroll IA, Healey JS, Abraham WT, Khaykin Y, Aleong R, Krueger SK, Sauer WH, Wilton SB, Rienstra M, van Veldhuisen DJ, Anand IS, White M, Camm AJ, Ziegler PD, Marshall D, Bristow MR, Connolly SJ. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol. 2021 08; 14(8):e009591.
Score: 0.022
-
Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail. 2001 Jun; 7(2 Suppl 1):8-12.
Score: 0.022
-
Kalscheur MM, Saxon LA, Lee BK, Steinberg JS, Mei C, Buhr KA, DeMets DL, Bristow MR, Singh SN. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial. Heart Rhythm. 2017 06; 14(6):858-865.
Score: 0.016
-
O'Connell JB, Gilbert EM, Renlund DG, Bristow MR. Enoximone as a bridge to heart transplantation: the Utah experience. J Heart Lung Transplant. 1991 May-Jun; 10(3):477-81.
Score: 0.011
-
O'Connell JB, Renlund DG, Hammond EH, Wittwer CT, Yowell RL, DeWitt CW, Jones KW, Gay WA, Menlove RL, Bristow MR. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss. J Heart Lung Transplant. 1991 Mar-Apr; 10(2):217-21; discussion 221-2.
Score: 0.011
-
Hegewald MG, O'Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, Jones KW, Lassetter JE, Bristow MR. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. J Heart Transplant. 1989 Jul-Aug; 8(4):303-9; discussion 309-10.
Score: 0.010
-
Renlund DG, O'Connell JB, Bristow MR. Early rejection prophylaxis in heart transplantation: is cytolytic therapy necessary? J Heart Transplant. 1989 May-Jun; 8(3):191-3.
Score: 0.009
-
MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
Score: 0.009
-
Renlund DG, Gilbert EM, O'Connell JB, Gay WA, Jones KW, Burton NA, Doty DB, Karwande SV, Dewitt CW, Menlove RL, Herrick CM, Bristow MR. Age-associated decline in cardiac allograft rejection. Am J Med. 1987 09; 83(3):391-8.
Score: 0.008
-
Gilbert EM, Eiswirth CC, Renlund DG, Menlove RL, DeWitt CW, Freedman LA, Herrick CM, Gay WA, Bristow MR. Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection. Transplant Proc. 1987 Apr; 19(2 Suppl 1):45-53.
Score: 0.008
-
Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation. 2006 Dec 19; 114(25):2766-72.
Score: 0.008
-
Kinugawa K, Jeong MY, Bristow MR, Long CS. Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase. Mol Endocrinol. 2005 Jun; 19(6):1618-28.
Score: 0.007
-
Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Billingham ME. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol. 1983 Nov-Dec; 5(6):913-9.
Score: 0.006
-
Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002 Oct 02; 40(7):1248-58.
Score: 0.006
-
Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail. 2001 Jun; 7(2):114-21.
Score: 0.005
-
Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH, Daniels JR. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol. 1980 Sep-Oct; 2(5):487-515.
Score: 0.005
-
Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978 Jun; 62(6):873-9.
Score: 0.004
-
Taylor DO, Bristow MR, O'Connell JB, Price GD, Hammond EH, Doty DB, Karwande SV, Gay WA, Jones KW, Lapp? D, Renlund DG. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant. 1996 Oct; 15(10):1039-46.
Score: 0.004
-
Ma H, Hammond EH, Taylor DO, Yowell RL, Bristow MR, O'Connell JB, Renlund DG. The repetitive histologic pattern of vascular cardiac allograft rejection. Increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3). Transplantation. 1996 Jul 27; 62(2):205-10.
Score: 0.004
-
Renlund DG, Taylor DO, Ensley RD, O'Connell JB, Gilbert EM, Bristow MR, Ma H, Yanowitz FG. Exercise capacity after heart transplantation: influence of donor and recipient characteristics. J Heart Lung Transplant. 1996 Jan; 15(1 Pt 1):16-24.
Score: 0.004
-
Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, Renlund DG. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J. 1995 Jan; 129(1):197-9.
Score: 0.003
-
O'Connell JB, Bristow MR, Rasmussen LG, Ratkovec RM, Gay WA, Jones KW, Renlund DG. Cardiac allograft function with corticosteroid-free maintenance immunosuppression. Circulation. 1990 Nov; 82(5 Suppl):IV318-21.
Score: 0.003
-
Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989 Mar; 79(3):483-90.
Score: 0.002
-
Lurie KG, Bristow MR, Reitz BA. Increased beta-adrenergic receptor density in an experimental model of cardiac transplantation. J Thorac Cardiovasc Surg. 1983 Aug; 86(2):195-201.
Score: 0.002
-
Schroeder JS, Lamb IH, Bristow MR, Ginsburg R, Hung J, McAuley BJ. Prevention of cardiovascular events in variant angina by long-term diltiazem therapy. J Am Coll Cardiol. 1983 Jun; 1(6):1507-11.
Score: 0.002
-
Lurie KG, Billingham ME, Masek MA, Ginsburg R, Bristow MR, Harrison D, Reitz BA. Ultrastructural and functional studies on prolonged myocardial preservation in an experimental heart transplant model. J Thorac Cardiovasc Surg. 1982 Jul; 84(1):122-9.
Score: 0.001
-
Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978 Jun; 62(6):857-64.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|